MX2016005596A - Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. - Google Patents

Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas.

Info

Publication number
MX2016005596A
MX2016005596A MX2016005596A MX2016005596A MX2016005596A MX 2016005596 A MX2016005596 A MX 2016005596A MX 2016005596 A MX2016005596 A MX 2016005596A MX 2016005596 A MX2016005596 A MX 2016005596A MX 2016005596 A MX2016005596 A MX 2016005596A
Authority
MX
Mexico
Prior art keywords
deoxy
difluorotetrahydrouridines
synthetic route
intermediates
synthesizing
Prior art date
Application number
MX2016005596A
Other languages
English (en)
Other versions
MX363205B (es
Inventor
Mathieu Steven
Fang Frank
Choi Hyeong-Wook
Matthew Lewis Bryan
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2016005596A publication Critical patent/MX2016005596A/es
Publication of MX363205B publication Critical patent/MX363205B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201—Oxygen-containing compounds
    • B01J31/0209—Esters of carboxylic or carbonic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0237—Amines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a métodos e intermedios para sintetizar compuestos de 2'-deoxi-2',2'-difluorotetrahidrouridina.
MX2016005596A 2013-10-29 2014-10-29 Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas. MX363205B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896703P 2013-10-29 2013-10-29
PCT/US2014/062874 WO2015066162A1 (en) 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Publications (2)

Publication Number Publication Date
MX2016005596A true MX2016005596A (es) 2016-12-09
MX363205B MX363205B (es) 2019-03-13

Family

ID=51982743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005596A MX363205B (es) 2013-10-29 2014-10-29 Ruta sintetica para obtener 2'-deoxi-2',2'-difluorotetrahidrouridi nas.

Country Status (20)

Country Link
US (3) US9834576B2 (es)
EP (1) EP3063164B1 (es)
JP (1) JP6427567B2 (es)
KR (1) KR102272773B1 (es)
CN (1) CN105683209B (es)
AU (1) AU2014342402B2 (es)
BR (1) BR112016008855B1 (es)
CA (1) CA2926734C (es)
ES (1) ES2712877T3 (es)
HK (1) HK1223627A1 (es)
IL (1) IL244849B (es)
MX (1) MX363205B (es)
MY (1) MY176465A (es)
NZ (1) NZ718607A (es)
PH (1) PH12016500683A1 (es)
RU (1) RU2681939C2 (es)
SA (1) SA516371019B1 (es)
SG (1) SG11201602614XA (es)
WO (1) WO2015066162A1 (es)
ZA (1) ZA201602315B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY176465A (en) 2013-10-29 2020-08-11 Otsuka Pharma Co Ltd Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
JP2022552817A (ja) * 2019-10-08 2022-12-20 大塚製薬株式会社 高純度の２’－デオキシ－２’，２’－ジフルオロテトラヒドロウリジン及びその製造方法
CN113402573B (zh) * 2020-07-31 2023-06-20 集美大学 一种鞣质类化合物及其提取方法和应用
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
TWI821074B (zh) * 2021-12-25 2023-11-01 台灣神隆股份有限公司 製備希達路里定（cedazuridine）的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
CA2241255A1 (en) 1995-12-22 1997-07-03 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DE60144573D1 (de) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
FI112640B (fi) 2000-12-22 2003-12-31 Kone Corp Hissin turvalaite
US8114854B2 (en) 2006-06-21 2012-02-14 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
MY176465A (en) 2013-10-29 2020-08-11 Otsuka Pharma Co Ltd Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines

Also Published As

Publication number Publication date
AU2014342402B2 (en) 2018-11-01
HK1223627A1 (zh) 2017-08-04
PH12016500683B1 (en) 2016-05-30
JP2017500281A (ja) 2017-01-05
US9834576B2 (en) 2017-12-05
IL244849B (en) 2019-10-31
RU2681939C2 (ru) 2019-03-14
US10526362B2 (en) 2020-01-07
RU2016115523A (ru) 2017-12-04
NZ718607A (en) 2019-10-25
MX363205B (es) 2019-03-13
KR20160083021A (ko) 2016-07-11
CA2926734C (en) 2022-03-15
US20160237107A1 (en) 2016-08-18
SA516371019B1 (ar) 2018-01-23
KR102272773B1 (ko) 2021-07-02
JP6427567B2 (ja) 2018-11-21
US20200123189A1 (en) 2020-04-23
EP3063164B1 (en) 2018-12-05
SG11201602614XA (en) 2016-05-30
US11028119B2 (en) 2021-06-08
CN105683209A (zh) 2016-06-15
PH12016500683A1 (en) 2016-05-30
MY176465A (en) 2020-08-11
IL244849A0 (en) 2016-05-31
ZA201602315B (en) 2019-07-31
WO2015066162A1 (en) 2015-05-07
CA2926734A1 (en) 2015-05-07
BR112016008855A2 (es) 2017-08-01
US20180072768A1 (en) 2018-03-15
ES2712877T3 (es) 2019-05-16
RU2016115523A3 (es) 2018-06-05
EP3063164A1 (en) 2016-09-07
AU2014342402A1 (en) 2016-04-21
BR112016008855B1 (pt) 2023-01-17
CN105683209B (zh) 2019-03-08

Similar Documents

Publication Publication Date Title
PH12018501159A1 (en) Composition and methods for immunooncology
PH12016501763A1 (en) Multispecific antibodies
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12016500683B1 (en) Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34817A (es) Tienopirimidinas
MX2023006415A (es) Anticuerpos, usos y metodos.
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
IN2013MU00848A (es)
IN2014DN06738A (es)
NZ720106A (en) A process for the preparation of regadenoson
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
EA201690263A1 (ru) Улучшенные способы получения перампанеля
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
IN2013MU04030A (es)
MX2015009377A (es) Compuestos radiomarcados.
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6
IN2013CH05591A (es)
IN2013CH05395A (es)
IN2013CH00453A (es)
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол